Cisatracurium Injection, Solution
Product Images NDC 63323-417

This is a warning label for a medical injectable solution called Cisatracurium Besylate Injection, USP. This solution contains 10mg (base) per SmL sterile, Nonpyrogenic and is meant for intravenous injection. It is a paralyzing agent that can cause respiratory arrest, so facilities must have artificial respiration readily available. It must be refrigerated at 2° to 8°C (36°to 46°F) and protected from light. The solution is preservative-free and must be used within 21 days of removal from refrigeration, even if re-refrigerated.*

Cisatracurium besylate is an injection used only for intravenous purposes with a concentration of 2 mg per mL. The label displays instructions to peel off and apply to the syringe for administration. No additional information is provided.*

Cisatracurium Besylate Injection, USP is a medication that contains 20 mg of Cisatracurium per 10 mL, with a concentration of 2mg per mL. It is for intravenous use and comes in a 10mL multiple-dose vial with a 0.9% benzyl alcohol preservative. The medication is sterile, norpyrogenic, and contains benzenesulfonic acid to adjust the pH. The medication must be refrigerated within a temperature range of 2°C to 8°C, protected from light, and should not be frozen. When removed from refrigeration to room temperature, it should be used within 21 days, even if refrigerated. The medication is a paralyzing agent that causes respiratory distress, requiring immediate availability of artificial respiration facilities. The listed product is manufactured by Fresenius Kabi, and the company is located in Lake Zurich, IL 60047.*

CISATRACURIUM BESYLATE INJECTION, USP is a medication intended for intravenous use only. It contains 2 mg per mL of Benzyl Alcohol. The package includes an instruction to peel off and apply to a syringe. The date and time are not available.*

This is a medication called Cisatracurium Besylate Injection, used in ICUs for intravenous injection. It is a paralyzing agent that can cause respiratory arrest, so artificial respiration facilities must be immediately available. It comes in a single dose vial, with 200mg per 20mL (10mg per mL) and is preservative-free. The medication should be refrigerated at 2° to 8°C (36° to 46°F) and protected from light. After removing from refrigeration to room temperature, it should be used within 21 days, even if re-refrigerated. The medication is made by Fresenius Kabi and the lot/exp number is 402641C with NDC code 63323-418-01.*

This is a label for a medication called cisatracurium besylate injection, which should only be used intravenously in the ICU and has a concentration of 10 mg per mL. The label indicates that there is a peel-off section to apply to the syringe and a space to indicate the date and time the medication was administered.*